UBS reports 5.82% stake in Reviva Pharmaceuticals

Rhea-AI Filing Summary

UBS Group reports shared ownership of 746,095 shares (5.82%) of Reviva Pharmaceuticals Holdings, Inc. The Schedule 13G discloses that UBS Group and certain wholly owned subsidiaries hold 746,095 shares of common stock, with shared voting and dispositive power over those shares. The filing lists UBS Group's principal office in Zurich and identifies the securities by CUSIP 76152G209. The form is signed by a director on 05/07/2026 and indicates the ownership amount as of 03/31/2026.

Insights

Corporate Governance Analyst

UBS Group holds a 5.82% passive stake in Reviva Pharmaceuticals as of 03/31/2026.

UBS Group reports 746,095 shares (5.82%) of common stock with shared voting and shared dispositive power. The Schedule 13G classification typically signals an investment made in a passive or institutional context rather than an intent to influence control.

Ownership is reported on behalf of UBS and specified subsidiaries; the filing shows the parent/subsidiary structure but does not state any plans, transactions, or intended changes. Subsequent filings would be required if the ownership purpose or control intent changes.

Key Figures

Reported shares beneficially owned: 746,095 shares Percent of class: 5.82% Sole voting power: 0 shares +4 more

7 metrics

Reported shares beneficially owned 746,095 shares Amount beneficially owned reported on Schedule 13G

Percent of class 5.82% Percent of common stock reported as beneficially owned

Sole voting power 0 shares Sole power to vote or to direct the vote

Shared voting power 746,095 shares Shared power to vote or to direct the vote

CUSIP 76152G209 Identifier for Reviva Pharmaceuticals common stock

Ownership as of 03/31/2026 Reporting date for the ownership amount

Filing signature date 05/07/2026 Date the Schedule 13G was signed by a director

Key Terms

beneficially owned, shared dispositive power, Schedule 13G, parent holding company

4 terms

beneficially owned regulatory

"Amount beneficially owned: 746,095 (b) Percent of class: 5.82%"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared Dispositive Power 746,095.00"

Schedule 13G regulatory

"This statement on is being filed by UBS Group AG on behalf of itself and its wholly owned subsidiaries"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

parent holding company regulatory

"If a parent holding company has filed this schedule, pursuant to (ii)(G), so indicate under Item 3(g)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does UBS Group report in Reviva Pharmaceuticals (RVPH)?

UBS Group reports beneficial ownership of 746,095 shares, representing 5.82% of Reviva Pharmaceuticals' common stock as disclosed in the filing. The ownership amount is reported as of 03/31/2026.

Does UBS Group have sole voting control over RVPH shares?

No. UBS Group reports 0 shares of sole voting power and 746,095 shares of shared voting power and shared dispositive power over the reported holdings.

Which entities filed the Schedule 13G for UBS Group?

The Schedule 13G was filed by UBS Group AG on behalf of itself and wholly owned subsidiaries including UBS Financial Services Inc., UBS Securities LLC, UBS Switzerland AG, and UBS AG London Branch as stated in the filing.

What date anchors the ownership reported by UBS Group for RVPH?

The filing indicates the ownership amount is reported as of 03/31/2026, and the Schedule 13G was signed on 05/07/2026 by a director representing the filer.

What does filing a Schedule 13G generally indicate about UBS Group's intent?

A Schedule 13G filing typically indicates an institutional or passive investor reporting beneficial ownership of more than 5% without declaring intent to influence control. The filing itself does not state any change-of-control intentions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 12:56 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

REVIVA PHARMACEUTICALS HOLDINGS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

76152G209

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 76152G209

1

Names of Reporting Persons

UBS Group AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 746,095.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 746,095.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

746,095.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

BK

SCHEDULE 13G

Item 1.
(a)	Name of issuer: REVIVA PHARMACEUTICALS HOLDINGS, INC.
(b)	Address of issuer's principal executive offices: 10080 N WOLFE ROAD, SUITE SW3-200, CUPERTINO, CALIFORNIA, 95014
Item 2.
(a)	Name of person filing: UBS Group AG
(b)	Address or principal business office or, if none, residence: Bahnhofstrasse 45 PO Box CH-8021, Zurich, Switzerland
(c)	Citizenship: Switzerland
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 76152G209
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 746,095
(b)	Percent of class: 5.82%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 746,095
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 746,095
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by UBS Group AG on behalf of itself and its wholly owned subsidiaries UBS Financial Services Inc.,UBS Securities LL,UBS Switzerland AG and UBS AG London Branch.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

UBS Group AG

Signature:	Andrew Johnson
Name/Title:	Director
Date:	05/07/2026